Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...